Boston, MA 05/30/2013 (wallstreetpr) – The share prices of Celsion Corporation (NASDAQ:CLSN) had increased by 39.47 percent to close at $1.59 per share for the end of last trading session. The shares of the company had been trading in the range of $1.15 to $1.59 per share during the day. The shares of Celsion Corporation (NASDAQ:CLSN) had recorded 52 week high price level of $9.44 per share and 52 week low price level of $0.75 per share.
Celsion Corporation (NASDAQ:CLSN) involved in the drug development for oncology with special focus on the development of treatment therapies for difficult to treat forms of cancer. The company’s recent product candidate ThermoDox is presently in the Phase III clinical trial for primary liver cancer, a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer.
The new product candidate of Celsion Corporation (NASDAQ:CLSN) is basically an encapsulation of doxorubicin which is popularly used in the treatment of various forms of cancer. The trading volume of Celsion Corporation (NASDAQ:CLSN) witnessed a heavy surge with nearly 29.07 million shares being exchanged hands for the day, while the average trading volume for the company is at 2.82 million shares per day. This heavy surge in trading volume for the oncology drug development company had pushed it into the volume gainers list.
The company presently holds 37.30 million shares outstanding with an institutional ownership of 34 percent of its holdings. The present market capitalization of Celsion Corporation (NASDAQ:CLSN) is at $59.31 million.
